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Abstract: Behçet's disease (BD) is an enigmatic inflammatory disorder, with vasculitis (perivasculitis) underlying patho-
physiology of its multisystemic affections. Venous pathology and thrombotic complications are hallmarks of BD. How-
ever, it has been increasingly recognized that cardiac involvement and arterial complications (aneurysms, pseudoaneu-
rysms, rupture and thrombosis) are important part of the course of BD. Pericarditis, myocardial (diastolic and/or systolic 
dysfunction), valvular and coronary (thrombosis, aneurysms, rupture) involvement, intracardiac thrombi (predominantly 
right-sided) are, probably, the most frequent cardiac manifestations. Treatment of cardiovascular involvement in BD is 
largely empirical and aimed at suppression of vasculitis. The most challenging seems to be the treatment of arterial aneu-
rysms and thromboses due to the associated risk of bleedings. Cardiologists should always bear in mind potential threats 
of (a)symptomatic cardiovascular involvement in BD. 
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INTRODUCTION 
  Over the past decade, pathophysiology of cardiovascular 
disease has been substantially revised and enriched with new 
facts  and  mechanisms  of  atherothrombogenesis  associated 
with inflammation and immune disorders. Based on the re-
cent numerous experimental and clinical studies, the concept 
of  premature  cardiovascular  disease  has  been  formulated, 
which paved ways for more efficacious preventive strategies 
[1].  It  has  also  become  obvious  that  further  investigation  
of  cardiovascular  involvement  in  inflammatory  disorders, 
particularly with persistent low-grade inflammation,  would 
be instrumental for better understanding of the accelerated 
course  of  atherothrombotic  diseases  and  adverse  vascular 
events  in  subjects  at  a  relatively  young  age  [2].  In  this  
regard, it is of great importance to analyze facts of cardio-
vascular involvement in Behçet’s disease (BD), to consider  
it as a prime example of thrombotic disease associated with  
T-cell  mediated  neutrophilic  inflammation,  and  to  outline 
features  of  thrombosis,  distinguishing  BD  from  other  
inflammatory disorders. 
  Notably, the issue of cardiovascular involvement in BD, 
which was thought to be relatively rare manifestation of the 
disease,  has  attracted  much  attention  of  cardiologists  over 
the past few decades, owing to the wide-spread use of highly 
informative  diagnostic  techniques,  such  as  echocardiogra-
phy,  Doppler  cardiography,  angiography,  computed  tomo-
graphy. As a result, staggering amount of reports, indicating 
both symptomatic and asymptomatic involvement of differ-
ent  structures  of  the  heart  and  all  types  of  vessels  with 
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predominantly right-sided heart disease and venous throm-
botic pathology, has been published [3-11].  
  The aim of the current communication is to outline the 
issue of cardiovascular involvement in BD and present some 
rare cases of interest for cardiologists.  
HISTORY AND CLASSIFICATION 
  BD  is  a  chronic  inflammatory  disorder  with  multisys-
temic manifestations. It is believed that primary descriptions 
of symptoms resembling BD can be found in the works of 
Hippocrates [12] and ancient scholars of traditional Chinese 
medicine [13]. Originally,  the disease described by Hulûsi 
Behçet  as  a  triad  of  recurrent  oral  and  genital  aphthous  
ulcerations and iritis in 1937 [14]. However, there were also 
earlier  scientific  reports  of  a  case  of  relapsing  iritis,  hy-
popyon, leg ulcerations and thrombophlebitis by Benediktos 
Adamantiades  in  1930-1931  [15,  16],  who,  later  on,  pub-
lished two more similar cases, described thrombophlebitis as 
the forth symptom, and classified the constellation of symp-
toms as a nosological entity [16]. This is why some authors 
proposed the term ‘Adamantiades-Behçet’s disease’ to pay 
tribute to the doctors, who equally contributed to the descrip-
tion  of  the  disease.  There  was  also  suggestion  to  use  the  
term ‘silk route disease’ to stress out geographic origin and 
primary spreading of BD through the ancient ‘silk route’ [17, 
18]. Thorough investigation of clinical, immunological and 
genetic  features  of  BD  led  to  its  classification  within  the 
frames of systemic vasculitides, seronegative spondyloarthri-
tides  and,  more  recently,  autoinflammatory  disorders  [19, 
20]. 
  Autoinflammatory disorders are heteregenous inflamma-
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Crohn’s  disease,  gout,  sharing  some  common  features  of 
inflammation  and  clinical  manifestations.  Etiology  and 
pathophysiology of these disorders still remain obscure. To 
date,  no  specific  etiological  agents,  antibodies  or  antigen 
specific immune cells responsible for inflammatory attacks 
or persistent subclinical inflammation in these disorders have 
been  identified.  FMF  is  one  of  the  most  common  autoin-
flammatory  disorders,  sharing  several  important  features 
with  BD  (e.g.,  frequent  detection  of  mutations  encoding 
pyrin protein, periodic inflammatory attacks with neutrophils 
as  target  cells,  good  response  to  colchicine)  [21].  Impor-
tantly, the latest classification of BD within the autoinflam-
matory disorders may provide clues for better understanding 
of factors involved in vascular pathology in this disease. At 
least, it was found out that patients with BD carrying Medi-
terranean  Fever  (MEFV)  mutations  are  prone  to  vascular 
pathology [22], which is, probably, suggestive of the impor-
tance  of  neutrophilic  reactions  and  potential  therapeutic  
implications  of  colchicine  in  vascular  pathology  in  BD.  
It would be also worth studying features of atherosclerotic 
disease within the autoinflammatory disorders. Interestingly, 
evidence  derived  from  observational  studies  with  carotid 
intimal-medial thickness suggests  that  BD patients  are not 
prone to atherosclerotic disease [23], whereas the same evi-
dence in FMF suggests the opposite [24]. Better understand-
ing of the differences in atherogenesis and in predominant 
vascular  lesions  in  BD  and  FMF  could  further  elucidate 
mechanisms of inflammation associated vascular pathology. 
EPIDEMIOLOGY AND PATHOPHYSIOLOGY 
  While  etiology  of  BD  remains  unknown,  ethnic  back-
ground,  gender-related  factors,  HLA  markers,  T-lympho- 
cytes  dysfunction,  circulating  immune  complexes,  geneti-
cally  predisposed  inflammation  and  hypercoagulation  are 
thought to be intimately involved in pathophysiology of BD 
[25, 26]. 
  BD is common in countries along the ancient Silk Route 
(from  the  Far  East  to  the  Mediterranean  region).  Turkey, 
Japan, Korea, China, Iran, Saudi Arabia are among the coun-
tries  with  a  high  prevalence  of  the  disease  (13.5-370  per 
100,000 population) [26]. In Western countries estimates of 
prevalence  are  much  lower  (0.12-5.2  per  100,000  popula-
tions)  [27].  In  Eastern  Mediterranean  and  Middle  Eastern 
countries  BD  is  more  common  among  the  middle-aged 
males,  who  suffer  from  more  aggressive  course  of  the  
disease than females [28].  
  Of  diverse  HLA  markers,  only  HLA-B51  allele  was 
found  to  be  strongly  associated  with  BD,  and  it  is  quite 
common in patients from countries along the Silk Route (up 
to 81%) [26]. It is, however, believed that not only genetic 
markers  but  also  environmental  factors  may  influence  the 
expression and course of the disease. In fact, expression of 
BD among Turks from Turkey, Germany and USA sharing 
the same genotype differs, with substantially higher preva-
lence of the disease in Turkey [29]; the same tendency was 
noted among Japanese subjects from different countries [30]. 
Additionally,  expression  of  heat  shock  protein  60,  non-
infectious  and  Th1-meditated  neutrophilic  activation,  
immune  reactions  triggered  by  Streptococcus  sanguis  and 
Herpes simplex virus are frequently considered as links in 
the pathophysiological chain of BD [31]. 
DIAGNOSTIC CRITERIA 
  Owing  to  the  lack  of  specific  clinical  and  laboratory  
diagnostic tests, several sets of diagnostic criteria have been 
proposed over the past decades. Of these, criteria by the BD 
Committee of Japan (1987, revised in 2003) [31] and Inter-
national Study Group for BD (1990) [32] are relatively well 
validated and in the use worldwide. Based on the Interna-
tional  Study Group for  BD  criteria,  the diagnosis requires 
presence of recurrent oral ulceration plus at least two other 
criteria  (recurrent  genital  ulceration,  ocular  signs,  skin  
lesions, positive pathergy test). This set is simpler. Japanese 
set includes major (oral ulcers, skin lesions, including subcu-
taneous  thrombophlebitis  and  cutaneous  hypersensitivity, 
eye lesions, genital ulcers or scars) and minor criteria (arthri-
tis,  gastrointestinal  lesions,  epididymitis,  vascular  lesions, 
central nervous system complications). For the definite diag-
nosis presence of four major criteria is mandatory. Both sets 
lack  in  the  appreciation  of  the  importance  of  a  variety  of 
venous and arterial lesions, and thromboembolic complica-
tions, frequently reported as part of initial, oligosymptomatic 
or classical, overt clinical presentation of BD.  
  Diagnostic uncertainties also include the issue of cardiac 
involvement.  Perhaps,  the  diagnosis  of  cardio-BD  in  the 
young  subjects  originating  from  countries  along  the  Silk 
Route should be considered even in cases when major (clas-
sical) criteria, such as oral ulcerations or positive pathergy 
test, are absent. In these cases, detailed analysis of the heart 
and large vessels structures and functions by echocardiogra-
phy, magnetic resonance imaging (MRI), CT, and a proper 
follow-up will be required. 
CARDIOVASCULAR INVOLVEMENT  
  The  morphological  basis  of  systemic  manifestations  in 
BD, including cardiovascular involvement, is vasculitis [33]. 
More  specifically,  some  pathologists  consider  perivascular 
structures  as  the  main  target  of  T-lymphocytes  mediated 
immune  reactions  and  ‘perivasculitis’  as  an  essential  part  
of vasculopathy in BD [34, 35]. Importantly, vasculopathy  
in BD is not associated with anti-Ro, antiphospholipid and 
antineutrophil  cytoplasmic  antibodies  (ANCA)  as  in  other 
systemic vasculitides and autoimmune diseases. 
  The venous and arterial wall lesions attract cytokinergic 
and neutrophilic reactions. The activated neutrophils leave 
destructive  effect  by  excessive  production  of  superoxide 
anion radicals and lysosomal enzymes. Neutrophilic infiltra-
tion and advanced vascular wall destruction with aneurysms 
formation cause local blood flow abnormalities. Endothelial 
dysfunction, release of von Willebrand factor, platelet acti-
vation, enhanced thrombin and fibrin generation, antithrom-
bin deficiency and impaired fibrinolysis  close pathological 
chain of enhanced thrombocoagulation associated with vas-
culitis (perivasculitis) in BD [36, 37]. Actually, pathological 
thrombosis in  BD  can be best viewed  within  the  classical 
Virchow’s triad. 
  Estimates of cardiovascular involvement in BD reach 7-
46%,  with  lethal  outcomes  in  about  20%  of  severe  cases 
[38]. As it is shown in multiple series of large observations, 
recurrent thrombophlebitis is the commonest vascular affec-
tion in BD [3]. Generally, venous involvement is reported in 
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rior vena cava and aorta bear the worst prognosis for patients 
with BD. Blood clots can develop in the deep veins of the 
lower extremity and migrate to the right heart and pulmonary 
arteries [40]. Destruction of  elastic  structures of  aorta can 
result  in  formation  of  aneurysms  and  pseudoaneurysms 
prone to rupture. Aneurysms of smaller vessels can also de-
velop, sometimes spontaneously. The risk of aneurysms and 
pseudoaneurysms  is  especially  high  in  those,  undergoing 
major (coronary artery bypass grafting, angioplasty of aorta 
and its branches) or even minor vascular interventions (e.g., 
arterial puncture) [8, 10, 41]. Coronary artery aneurysms are 
another major challenge in terms of diagnosis, cardiovascu-
lar risk assessment and treatment in BD. This type of coro-
nary  pathology  clinically  manifests  as  MI  at  a  relatively 
young age without strong association with classical cardio-
vascular risk factors [10].  
  With  the  use  of  echocardiography  other  less  frequent 
symptomatic or asymptomatic manifestations have also been 
reported  (Table  1):  pericarditis,  endocarditis,  myocarditis,  
ventricular thromboses (predominantly right-sided), cardio-
myopathy  with  severe  systolic  dysfunction  and  valvular  
affections [38, 42].  
Table 1.  Cardiac Manifestations in BD 
Detected by Echocardiography and MRI 
Pericarditis 
Interatrial septal aneurysms, left atrial dilatation 
Left ventricular diastolic and systolic dysfunction 
Endocarditis 
Endomyocardial fibrosis 
Right and left ventricular aneurysms and thrombi 
Aneurysmatic enlargement of sinus valsalvae and ascending aorta 
Mitral prolaps with or without regurgitation 
Coronary aneurysms 
Detected by Electrocardiography 
Atrioventricular conduction disturbances (up to severe blockade and 
bradycardia) 
Left and right bundle branches blockade 
QT prolongation 
Abnormal late potentials 
Ectopic arrhythmias 
 
  In our own practice, we have examined 44 patients with 
BD and cardiovascular involvement referred from ophthal-
mologists  and  dermatologists.  To  demonstrate  complexity 
and  variety  of  cardiovascular  manifestations  in  BD,  we  
present some cases from own practice. 
Case 1 
  A 66-year-old male patient, who lived in Switzerland and 
whose parents were originally from Turkey and Azerbaijan, 
was diagnosed with BD in 2004, based on ocular symptoms, 
erythema nodosum, positive pathergy test and typical vascu-
litis described on biopsy specimens from erythematous area. 
The  patient  was  treated  with  methotrexate,  colchicine  and 
corticosteroids with substantial improvement of ocular and 
mucocutaneous symptoms. In the absence of classical car-
diovascular  risk  factors,  the  patient  developed  myocardial 
infarction with ST elevation (STEMI) and positive enzyme 
tests.  On  coronarography,  large  aneurismal  lesions  of  left 
marginal and left descending coronary artery were detected. 
Coronary  angioplasty  was  unsuccessful,  with  ventricular 
fibrillation  requiring  electrical  cardioversion.  Later,  the  
patient  was  discharged  from  the  hospital  on  aspirin,  
clopidogrel,  beta-blocker  and  peripheral  calcium-channel 
blocker,  corticosteroids  and  cyclosporine.  After  6  months, 
cyclosporine was discontinued because of worsened glome-
rular filtration rate and advanced heart failure (NYHA III). 
Importantly, at that time laboratory tests revealed high levels 
of  proBNP  (up  to  2,246  pg/mL).  On  ECG  performed  in 
2008, there were occasional extrasystoles and pathological Q 
waves  (old  anteroseptal  MI)  (Fig.  1a).  Echocardiography 
revealed  decreased  left  ventricular  ejection  fraction  (EF) 
(<36%),  altered  mitral  flow  [early  diastolic/atrial  flow 
(E/A)=0.5,  fusion  of  E  and  A  waves)].  MRI  showed  
apical aneurysm with 2.5x2.3 cm calcified apical thrombus 
(Fig. 1b). 
Case 2 
  A  52-year-old  woman  (Swiss  father,  Greek  mother),  
living  in  Switzerland  since  the  age  of  32,  was  referred  
for consultation with  established diagnosis of  BD in 2002 
(recurrent  oral  ulcerations,  retino-uveitis,  erythema  nodo-
sum,  perivasculitis  in  biopsy  specimens).  The  patient  was 
treated  with  corticosteroids,  methotrexate  and  colchicine. 
The  cutaneous  and  mucosal  pathology  improved  dramati-
cally. In 2005, she experienced suddenly developed dyspnea 
(NYHA  II-III)  and  palpitations.  New  heart  murmurs  were 
detected. Besides, there were also several other signs of car-
diac pathology: pathologic right apical bulging; marked and 
permanent splitting of the 2
nd heart sounds, 4/6 degree tri-
cuspid, 3/6 degree mitral regurgitation murmur; 2/6 systolic 
aortic and 2/6 diastolic murmurs over aorta; premature beats 
(supraventricular  and  ventricular  in  origin)  and  complete 
right bundle branch block on ECG; aneurysmal motion of 
the interatrial septum, dilatation of the sinus coronarius, mild 
mitral  regurgitation,  myxoid  mitral  and  tricuspid  valves,  
enlarged annulus of the thickened aortic valve, and severe 
mitral regurgitation on echocardiography (Fig. 2 a, b, c). The 
calculated mean pulmonary pressure was 38 mmHg. Spiral 
CT  excluded  pulmonary  lesions  and  embolization.  The  
patient  was  treated  with  aspirin,  diuretics  and  carvedilol. 
Occurrence of symptomatic paroxysmal atrial fibrillation and 
complex  ventricular  arrhythmias  were  successfully  treated 
with amiodarone. Lately, the patient was asymptomatic and 
continued treatment with aspirin and carvedilol. On echocar-
diography there were features of myxoid mitral and tricuspid 
valves  with  insignificant  mitral  and  moderate  tricuspid  
regurgitation.  The  interatrial  septum  was  thickened  but  
without  aneurysm.  The  mean  pulmonary  pressure  was  
normal (18 mmHg). 
Case 3 
  A  66-year-old  female  patient  (father  from  Algeria, 
mother from Afghanistan), who had been living in Switzer-
land since the age of 24, was diagnosed with BD in 2003 
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positive  pathergy  test).  She  was  treated  with  high-dose  
corticosteroids  in  combination  with  cyclophospamide  and 
colchicine. Non-cardiac symptoms ameliorated. In 2005, she 
was diagnosed with heart failure. On physical examination – 
mitral and aortic regurgitation murmurs, on ECG – I degree 
AV blockade, left ventricular hypertrophy, non-specific ST 
changes; on echocardiography – II degree mitral and aortal 
regurgitation, enlarged sinus coronarius and aortic root (Fig. 
3a), and diastolic dysfunction (Fig. 3b). Due to the worsen-
ing  of  mitral  regurgitation,  the  patient  underwent  mitral 
valvuloplasty 3 years later. 
Case 4 
  A  54-year-old  Italian  male  patient  was  diagnosed  with 
BD in 2002 (recurring genital ulcers, iridocyclitis, epididym-
itis, vasculitis with perivascular mononuclear infiltration on 
biopsy).  He  was  treated  with  high-dose  corticosteroids, 
methotrexate and colchicine with a substantial improvement 
of non-cardiac symptoms. In 2004, the patient presented with 
dyspnea  (NYHA  II)  and  diastolic  murmur  over  the  aorta. 
Echocardiography showed thickened aortic valve  and mild 
dilatation of the ascending aorta (Fig. 4). There were also 
signs of left ventricular diastolic dysfunction with preserved 
systolic function. Candesartan and carvedilol were added to 
the treatment. Dyspnea disappeared. On echocardiography, 
performed  9  months  later,  there  were  no  signs  of  aortic  
dilatation. Diastolic dysfunction disappeared two years later.  
Case 5 
  A 55-year-old Greek male patient, who lived in Switzer-
land since the age of 20, was diagnosed with BD in 2002 
(recurrent oral aphthous ulcerations, genital ulcers, phlebitis, 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1a). Occasional extrasystoles and pathological Q waves in the anterior and inferior leads. 
 
 
 
 
 
 
 
 
 
 
Fig. (1b). MRI image of enlarged left ventricle with a large intracardiac calcified thrombus. 
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Fig. (2a). Mitral regurgitation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2b). 3D-echocardiographic cross-sectional image of the heart: thickened mitral valve (left-side) and papillary muscles of the tricuspid 
valve (right-side).  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2c). 3D-echocardiographic cross-sectional image of the heart: thickened anterior papillary muscle of the mitral valve (left-side) and 
thickened papillary muscles of the tricuspid valve (right-side).  68    The Open Cardiovascular Medicine Journal, 2010, Volume 4  Cocco and Gasparyan 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3a). Myxoid mitral and aortic valves and enlarged sinus coronarius.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3b). Transmitral blood flow suggestive of diastolic dysfunction (impaired relaxation): reduced E/A ratio, prolonged deceleration time of 
the E wave, and a fusion of E and A waves.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Thickened aortic valve and enlarged ascending aorta.  Behçet’s Disease  The Open Cardiovascular Medicine Journal, 2010, Volume 4    69 
 
erythema nodosum, positive pathergic test), and was treated 
with  high-dose  corticosteroids,  methotrexate,  colchicine. 
Non-cardiac  symptoms  responded  to  the  treatment.  ECG 
showed  mild  left  ventricular  hypertrophy  with  nonspecific 
changes of T wave. Two years later, the patient developed 
non-ischemic chest pain, dyspnea (NYHA II), and ECG re-
vealed left ventricular hypertrophy, with marked horizontal 
ST depression in I, II and V4-6 leads, and giant, negative  
T waves in I, II, aVF, V4-6 (resembling changes of apical 
cardiomyopathy) (Fig. 5). On echocardiography there were 
signs  of  left  ventricular  medial  and  apical  endocardial  
fibrosis with advanced diastolic dysfunction (similar to the 
changes in Fig. 3b). There was also blood pressure elevation 
from  130/80  mmHg  (2002)  to  160/100  mmHg  (2004).  
Therapy  with  candesartan,  amlodipine  and  carvedilol  was 
initiated  with  blood  pressure  normalization  and  cardiac 
symptoms improvement. However, electrocardiographic and 
echocardiographic findings remained unchanged. 
TREATMENT 
  Treatment of BD is still based on low level of evidence 
(experts’  opinion)  [43].  Corticosteroids  along  with  cyclo-
phosphamide,  methotrexate,  azathioprine,  cyclosporine  
colchicine provide remissions of variable duration in most 
patients. Experience with the use of anti-TNF agents in BD 
has  advanced  in  the  past  decade.  Some  studies  and  case  
reports  are  also  suggestive  of  successful  treatment  of  BD 
with thalidomide and lenalidomide [44, 45]. Colchicine was 
shown to be effective, particularly in cases of pericarditis, in 
numerous Middle Eastern observations. Oral anticoagulants 
and  antiplatelets  are  often  used  to  treat  thromboembolic 
complications  in  BD.  However,  antithrombotic  therapy 
should  be  administered  cautiously,  given  the  proneness  of 
BD  patients  to  bleedings,  particularly  from  symptomatic  
or  asymptomatic  pulmonary  aneurysms.  From  the  other 
hand,  combined  therapy  of  thalidomide  or  lenalidomide  
with corticosteroids should be under scrutinized monitoring 
of thrombosis and coagulation markers, because of an asso-
ciated substantially increased risk of deep vein thrombosis 
[46, 47]. 
  Taken together, not much is known about efficacy and 
safety of treatment of cardiovascular manifestations in BD. 
Conventional  drug  treatment  of  acute  coronary  syndromes  
in  BD,  which  can  be  caused  by  ruptured  aneurysms,  is  
not  balanced  against  possible  treatment  induced  hazards. 
Severe  myocardial  ischemia  can  be  treated  with  coronary  
angioplasty. However, given the risk of spontaneous dissec-
tions  and  secondary  aneurysms,  this  therapeutic  option 
seems to be unsafe. Treatment of arrhythmias in BD is also 
challenged. One of the numerous serious issues is electroim-
pulse therapy with transient or permanent pacemakers, which 
can be complicated with secondary aneurysms. 
CONCLUSIONS 
  Cardiovascular manifestations in BD are numerous, and 
their  relationships  with  non-cardiac  features  are  not  well 
explored. Main cardiac features of BD include pericarditis, 
myocardial (diastolic and/or systolic dysfunction), valvular, 
coronary (thrombosis, aneurysms, rupture) and intracardiac 
thrombus  (predominantly  right-sided).  Several  cardiac  
manifestations  may  coincide  in  one  patient.  Cardiologists 
should  always  bear  in  mind  potential  threats  of 
(a)symptomatic cardiovascular involvement in BD and con-
sider  non-invasive  diagnostic  measures  (echocardiography, 
CT, MRI) for its timely detection. Treatment of cardiovascu-
lar  manifestations  is  not  well  explored  and  there  are  still  
major  concerns  over  the  safety  of  drug  treatments  and  
angioplasties.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). ECG signs of left ventricular hypertrophy; horizontal ST depression in I, II and V4-6 and giant inverted T waves in I, II, aVF, V4-6. 
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